Personalized dosing tested for stubborn skin cancer
NCT ID NCT05651828
Summary
This study compares four different dosing schedules of the drug vismodegib for people with advanced basal cell carcinoma, a type of skin cancer. Researchers want to see if personalized, on-and-off dosing schedules work better and are more tolerable than standard continuous or fixed intermittent dosing. The trial will enroll 34 adults to find the most effective approach for controlling this cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33617, United States
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.